Alkermes plc is preparing to launch Lybalvi (olanzapine/samidorphan) in the fourth quarter as a new treatment option for schizophrenia and bipolar I disorder with less weight gain than traditional olanzapine, and the company is guiding investors to expect a gradual ramp up as patients cycle through the various treatment options already available, including generics.
Lybalvi (previously ALKS 3831) cleared the US Food and Drug Administration 1 June for treatment of schizophrenia in adults as well as treatment of bipolar I disorder in adults, including...